Neuromodulation Devices: World Market Prospects 2011-2021
NEW YORK, Nov. 28, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:
Neuromodulation Devices: World Market Prospects 2011-2021
http://www.reportlinker.com/p0692159/Neuromodulation-Devices-World-Market-Prospects-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Our latest pharma report - Neuromodulation Devices: World Market Prospects 2011-2021 - offers a comprehensive view of the global neuromodulation devices market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict the global value of the neuromodulation devices market in 2011 to be worth $3.05bn. The market has significant potential for growth with the increasing global burden of neurological and cardiovascular disorders, especially in the emerging economies. Growth in this market will also be driven by the approval and launch of neuromodulation devices that are more effective and involve a more simplified, less-invasive implantation procedure.
Neuromodulation is one of the fastest growing sectors of the medical device market. Neuromodulation is a rapidly evolving medical technique that provides symptomatic relief through the alteration, or modulation, of nerve system function. It works by either stimulating nerves to produce a natural biological response or by applying small doses of pharmaceutical agents directly to the site of action.
Visiongain's research suggests that the neuromodulation devices market will benefit from the growth of healthcare markets in the emerging economies. The growth in emerging markets such as India and China will be driven by an aging population that will increase demand for newer treatment options for age-related diseases. India's expanding economy is likely to see an increased wealth among the population, specifically within the middle class, which will cause an increased adoption of westernised lifestyles. Diseases such as obesity and coronary heart disease will therefore become more prevalent. The neuromodulation devices market in the emerging economies will also benefit from a rise in demand for non-invasive treatment options and medical tourism.
The Neuromodulation Devices: World Market Prospects 2011-2021 examines the spinal cord stimulaiton, deep brain stimulation and vagus nerve stimulation with respect to the market size, leading companies and products, and promising products in the pipeline. Visiongain predicts that this market will grow steadily to 2021, primarily driven by a rise in age-related diseases, approval of innovative devices, and increased patient adoption of existing and newly-marketed products.
How will the neuromodulation devices market develop this decade? Which regions offer the most significant growth opportunities between 2011 and 2021? Which of the neuromodulation devices submarkets are growing most strongly? Who are the leading companies in the neuromodulation devices market? What are the most promising neuromodulation devices in development and when are they expected to receive market approval?
Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.
Detailed analysis of the global Neuromodulation Devices Market
Neuromodulation Devices: World Market Prospects 2011-2021 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are 93 tables and figures included, as well as two full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Why you should buy Neuromodulation Devices: World Market Prospects 2011-2021
In this report, you will receive the following benefits in particular:
- You will receive our assessment of the current market for neuromodulation devices, with respect to the leading segments, products, companies and national markets
- You will discover sales trends for the overall neuromodulation devices market from 2011 to 2021 - seeing where commercial growth will occur
- You will discover sales trends for the main segments - spinal cord stimulation, deep brain stimulation and vagus nerve stimulation - from 2011 to 2021, with detailed discussions of market potential
- You will receive sales forecasts for leading geographical markets (US, Japan,Germany, France, Italy, Spain, UK, China and India), with informed discussion
- You will assess leading companies in the neuromodulation devices market along with their marketed and pipeline products
- You will receive our analyses of the future of neuromodulation devices market, including assessment of some products in the R&D pipeline
- You will examine the strengths, weaknesses, opportunities and threats (SWOT analysis) facing the neuromodulation devices markets from 2011 onwards
- You will be able to investigate competition and opportunities influencing the neuromodulation devices market from 2011 onwards
- You will see what will stimulate and restrain the neuromodulation devices market from 2011
- You will discover the unmet needs in the market, driving the growth from 2011 onwards
- You will view expert opinion from our survey, including full interview transcripts.
You can obtain this report today
Anybody with an interest in the neuromodulation/neurostimulation devices industry should gain valuable information and insight from this new study by Visiongain, which analyses one of the most important neurological devices industries. Success in the neurological devices market from 2011 to 2021 will be characterised by the growth of neuromodulation devices market and launch of innovative products currently in the pipeline. You can find out about the developments in this industry and much more from this latest report from visiongain on Neuromodulation Devices: World Market Prospects 2011-2021. You can stay ahead by ordering this report today.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents
1. Executive Summary
1.1 Sector Highlights
1.2 Aims, Scope and Format of the Report
1.2.1 Chapter Outline
1.3 Research and Analysis Methods
1.4 Glossary of Terms Related to Neuromodulation Devices
2. An Introduction to Neuromodulation
2.1 Neuromodulation
2.2 Techniques Used in Neuromodulation
2.2.1 Electrical Stimulation Techniques
2.2.1.1 Brain and Spinal Cord Therapies
2.2.1.2 Cranial Nerve Stimulation
2.2.1.3 Functional Electrical Stimulation
2.2.2 Pharmacological Therapy
2.3 Application of Neuromodulation
2.3.1 Pain
2.3.1.1 Neuromodulation and Treatment of Pain
2.3.2 Depression
2.3.2.1 Neuromodulation and Treatment of Depression
2.3.3 Epilepsy
2.3.3.1 Neuromodulation and Treatment of Epilepsy
2.3.4 Urological Disorders: Overactive Bladder & Urinary Incontinence
2.3.4.1 SNS and Treatment of Urinary Incontinence
2.3.5 Hearing Disorders: Profound Deafness
2.3.6 Cardiac Disorders: Arrhythmias & Angina
2.3.6.1 Neuromodulation and Treatment of Cardiac Disorders
2.3.7 Parkinson's Disease
3. The Global Neuromodulation Devices Market, 2010-2021
3.1 Scope and Limitations
3.2 Neuromodulation Devices is the Largest Segment in the Neurological Medical Devices Sector
3.3 Neuromodulation Devices Market in 2010
3.3.1 SCS Devices Dominate the Neuromodulation Devices Market in 2010
3.4 Medtronic is the Market Leader in the Neuromodulation Devices Market
3.5 Neuromodulation Devices in the Market
3.6 Leading Companies in the Neuromodulation Devices Market, 2010
3.6.1 Medtronic
3.6.1.1 Medtronic Sales, 2010
3.6.1.2 Medtronic's DBS and SCS Devices in the Market
3.6.1.3 Medtronic's Product Pipeline
3.6.2 St. Jude Medical (SJM)
3.6.2.1 SJM Sales, 2010
3.6.2.2 SJM Neuromodulation Devices in the Market
3.6.2.3 SJM Product Pipeline
3.6.3 Boston Scientific
3.6.3.1 Boston Scientific Sales, 2010
3.6.3.2 Boston Scientific Neuromodulation Devices: Marketed and Pipeline
3.6.4 Cyberonics
3.6.4.1 Cyberonics Sales, 2010
3.6.4.2 Cyberonics Neuromodulation Devices: Marketed and Pipeline
3.6.5 IntraPace
3.7 Neuromodulation Devices Market Forecast, 2011-2016
3.8 Neuromodulation Devices Market Forecast, 2016-2021
3.9 Changing Market Shares of the Leading Segments
4. Spinal Cord Stimulation Devices Market, 2010-2021
4.1 The US was the Largest Market for SCS Devices in 2010
4.2 Medtronic Dominated the US SCS Devices Market, Closely Followed by SJM and Boston Scientific
4.3 SCS Devices Market Forecast, 2011-2016
4.4 SCS Devices Market Forecast, 2016-2021
4.5 Competition in the SCS Market: Companies and Products
4.5.1 Medtronic
4.5.2 Boston Scientific
4.5.3 St. Jude Medical
4.5.4 Nevro
5. Deep Brain Stimulation Devices Market, 2010-2021
5.1 DBS Devices Market in 2010: Medtronic is the Only Company With an FDA Approved DBS Device
5.2 DBS Devices Market Forecast, 2011-2016
5.3 DBS Devices Market Forecast, 2016-2021
5.4 Competition in the DBS Devices Market: Companies and Products
5.4.1 Medtronic
5.4.2 St. Jude Medical
6. Vagus Nerve Stimulation Devices Market, 2010-2021
6.1 The US Contributed 81.3% of the VNS Market Sales in 2010
6.2 Majority of Sales of the VNS Devices Was for the Treatment of Refractory Epilepsy in 2010
6.3 Cyberonics Dominated the VNS Market in 2010
6.3.1 Cyberonics is Set to Lose its Monopoly in the VNS Devices Market
6.4 VNS Devices Market Forecast, 2011-2016
6.5 VNS Devices Market Forecast, 2016-2021
6.6 Competition in the VNS Devices Market: Companies and Products
6.6.1 Cyberonics
6.6.2 CerebralRx (a spin-off of BioControl Medical)
6.6.3 EnteroMedics
7. Neuromodulation Devices Pipeline
7.1 CVRx
7.2 Apnex Medical
7.3 ImThera Medical
7.4 NeuroPace
7.5 Intelect Medical (acquired by Boston Scientific Corporation)
7.6 EnteroMedics
7.7 MetaCure
7.8 Other Companies and Products
8. Leading National Markets, 2010-2021
8.1 Leading National Markets in 2010
8.2 The US Market Forecast, 2011-2021
8.3 The Japanese Market Forecast, 2011-2021
8.4 Leading European Markets Forecast, 2011-2021
8.4.1 The German Market
8.4.2 The French Market
8.4.3 The UK Market
8.4.4 The Italian Market
8.4.5 The Spanish Market
8.5 The Chinese Market Forecast, 2011-2021
8.6 The Indian Market Forecast, 2011-2021
8.7 Rest of the World (RoW)
9. SWOT Analysis of the Neuromodulation Device Industry, 2011-2021
9.1 Strengths
9.1.1 Neuromodulation Can be Seen as Safer Than Alternative Treatments
9.1.2 A Cost Effective Treatment Option
9.1.3 Neuromodulation Often Means Less Medication
9.2 Weaknesses
9.2.1 Neuromodulation Mechanisms Are Not Well Understood
9.2.2 A Small Number of Large Companies Dominate the Market
9.2.3 FDA Approvals
9.2.4 Failing Clinical Trials
9.3 Opportunities
9.3.1 Neuromodulation Market Set for Rapid Growth: Expanding Disease Indications
9.3.2 Increasing Prevalence of Neurological Diseases
9.3.3 The Potential of Personalised Medicine
9.4 Threats
9.4.1 Parkinson's Disease May Soon be Treated with Stem Cells
9.4.2 SCS Faces Competition from Other Treatment Options
10. Expert Opinion
10.1 Interview with Michael Berman, Founder, Berman Medical
10.1.1 The Neuromodulation Market
10.1.2 Challenges Facing the Neuromodulation Market
10.1.3 Prospects for the Neuromodulation Market
10.2 Spokesperson from CVRx (Views Provided Anonymously)
10.2.1 Barostim neo: New Implantable Device for Hypertension
10.2.2 On the Development of Barostim neo
10.2.3 Competition for Barostim neo
10.2.4 On the Unmet Needs in the Market
10.3 Franck Fischer and Rebecca Kuhn, CEO and CFO, NeuroPace Inc
10.3.1 NeuroPace's RNS Neuromodulation System for Epilepsy
10.3.2 The Neuromodulation and the Epilepsy Markets
10.3.3 Public Perception and Understanding of Neuromodulation
10.3.4 Small Companies Surviving in the Industry
10.3.5 Educating Physicians About Neuromodulation
10.3.6 Neuromodulation's Role in Relation to Other Treatment Options
10.3.7 Recent Healthcare Reform in the US
10.3.8 Comparative Effectiveness Research
11. Conclusions
11.1 The Neuromodulation Devices Market is Dominated by Four Companies
11.2 The Neuromodulation Devices Market, 2011-2021
11.3 Neuromodulation Devices Will be Developed for New Indications: Driving Market Growth
11.4 Vast Opportunities for Growth in Emerging Markets
11.5 Introduction of Alternative Treatment Options Can Threaten Market Growth
Appendix A
Appendix B
Visiongain report evaluation form
List of Tables
Table 3.1 The Neurological Devices Market: Sales ($bn) and Market Share (%) by Sectors, 2010
Table 3.2 Global Neuromodulation Devices Market by Leading Segments: Sales ($bn) and Market Share (%), 2010
Table 3.3 Global Neuromodulation Devices Market ($m) by Company, 2010
Table 3.4 List of Some Approved/Marketed Neuromodulation Devices, 2011
Table 3.5 Medtronic Sales ($bn) by Business Segment, 2010 and 2009
Table 3.6 St. Jude Medical Sales ($bn) by Business Segment, 2010
Table 3.7 Boston Scientific Sales ($bn) by Business Segment, 2010
Table 3.8 Neuromodulation Devices Market: Sales Forecast ($bn), 2010-2016
Table 3.9 Neuromodulation Devices Market: Sales Forecast ($bn), 2016-2021
Table 3.10 Market Shares (%) of Leading Segments in the Neuromodulation Devices Market, 2010, 2016 & 2021
Table 4.1 SCS Devices Market: Regional Sales ($bn), 2010
Table 4.2 The US SCS Devices Market by Leading Companies ($m), 2010
Table 4.3 SCS Devices Market: Sales Forecast ($bn), 2010-2016
Table 4.4 SCS Devices Market: Sales Forecast ($bn), 2016-2021
Table 5.1 DBS Devices Market: Sales Forecast ($bn), 2010-2016
Table 5.2 DBS Devices Market: Sales Forecast ($bn), 2016-2021
Table 6.1 VNS Devices Market: Regional Sales ($m), 2010
Table 6.2 VNS Devices Market ($m) by Indication, 2010
Table 6.3 Cyberonics' VNS Therapy System: Unit Sales by Indication, 2010
Table 6.4 VNS Devices Market: Sales Forecast ($bn), 2010-2016
Table 6.5 VNS Devices Market: Sales Forecast ($bn), 2016-2021
Table 7.1 Neuromodulation Devices Pipeline, 2011
Table 7.2 Other Companies Involved in the Development of Neuromodulation Devices, 2011
Table 8.1 Leading National Markets: Sales ($bn) & Market Shares (%), 2010
Table 8.2 The US Neuromodulation Devices Market Forecast ($bn), 2010-2016
Table 8.3 The US Neuromodulation Devices Market Forecast ($bn), 2016-2021
Table 8.4 The Japanese Neuromodulation Devices Market Forecast ($bn), 2010-2016
Table 8.5 The Japanese Neuromodulation Devices Market Forecast ($bn), 2016-2021
Table 8.6 The German Neuromodulation Devices Market Forecast ($bn), 2010-2016
Table 8.7 The German Neuromodulation Devices Market Forecast ($bn), 2016-2021
Table 8.8 The French Neuromodulation Devices Market Forecast ($bn), 2010-2016
Table 8.9 The French Neuromodulation Devices Market Forecast ($bn), 2016-2021
Table 8.10 The UK Neuromodulation Devices Market Forecast ($bn), 2010-2016
Table 8.11 The UK Neuromodulation Devices Market Forecast ($bn), 2016-2021
Table 8.12 The Italian Neuromodulation Devices Market Forecast ($bn), 2010-2016
Table 8.13 The Italian Neuromodulation Devices Market Forecast ($bn), 2016-2021
Table 8.14 The Spanish Neuromodulation Devices Market Forecast ($bn), 2010-2016
Table 8.15 The Spanish Neuromodulation Devices Market Forecast ($bn), 2016-2021
Table 8.16 The Chinese Neuromodulation Devices Market Forecast ($bn), 2010-2016
Table 8.17 The Chinese Neuromodulation Devices Market Forecast ($bn), 2016-2021
Table 8.18 The Indian Neuromodulation Devices Market Forecast ($bn), 2010-2016
Table 8.19 The Indian Neuromodulation Devices Market Forecast ($bn), 2016-2021
Table 8.20 Rest of the World Neuromodulation Devices Market Forecast ($bn), 2010-2016
Table 8.21 Rest of the World Neuromodulation Devices Market Forecast ($bn), 2016-2021
Table 9.1 SWOT Analysis of the Neuromodulation Devices Market, 2011-2021
List of Figures
Figure 3.1 World Neuromodulation Devices Market Share (%) in the Neurological Devices Market, 2010
Figure 3.2 Market Shares (%) of Leading Segments in the Neuromodulation Devices Market, 2010
Figure 3.3 The Neuromodulation Devices Market ($bn) by Segments, 2010
Figure 3.4 Market Shares (%) of Leading Companies in the Global Neuromodulation Devices Market, 2010
Figure 3.5 Medtronic Sales Share (%) by Business Segment, 2010
Figure 3.6 St Jude Medical Sales Share (%) by Business Segment, 2010
Figure 3.7 Boston Scientific Sales Share (%) by Business Segment, 2010
Figure 3.8 Neuromodulation Devices Market: Sales Forecast ($bn), 2010-2016
Figure 3.9 Neuromodulation Devices Market: Sales Forecast ($bn), 2016-2021
Figure 3.10 Market Shares (%) of Leading Segments in the Neuromodulation Devices Market, 2016
Figure 3.11 Market Shares (%) of Leading Segments in the Neuromodulation Devices Market, 2021
Figure 4.1 SCS Devices Market Share (%) by Regions, 2010
Figure 4.2 Market Shares (%) of Leading Companies in the US SCS Devices Market, 2010
Figure 4.3 SCS Devices Market: Sales Forecast ($bn), 2010-2016
Figure 4.4 SCS Devices Market: Sales Forecast ($bn), 2016-2021
Figure 5.1 DBS Devices Market: Sales Forecast ($bn), 2010-2016
Figure 5.2 DBS Devices Market: Sales Forecast ($bn), 2016-2021
Figure 6.1 VNS Devices Market Share (%) by Regions, 2010
Figure 6.2 VNS Devices Market Share (%) by Indication, 2010
Figure 6.3 Cyberonics' VNS Therapy System Units Market Share (%) by Indication, 2010
Figure 6.4 VNS Devices Market: Sales Forecast ($bn), 2010-2016
Figure 6.5 VNS Devices Market: Sales Forecast ($bn), 2016-2021
Figure 8.1 Leading National Markets: Market Shares (%), 2010
Figure 8.2 The US Neuromodulation Devices Market Forecast ($bn), 2010-2016
Figure 8.3 The US Neuromodulation Devices Market Forecast ($bn), 2016-2021
Figure 8.4 The Japanese Neuromodulation Devices Market Forecast ($bn), 2010-2016
Figure 8.5 The Japanese Neuromodulation Devices Market Forecast ($bn), 2016-2021
Figure 8.6 The German Neuromodulation Devices Market Forecast ($bn), 2010-2016
Figure 8.7 The German Neuromodulation Devices Market Forecast ($bn), 2016-2021
Figure 8.8 The French Neuromodulation Devices Market Forecast ($bn), 2010-2016
Figure 8.9 The French Neuromodulation Devices Market Forecast ($bn), 2016-2021
Figure 8.10 The UK Neuromodulation Devices Market Forecast ($bn), 2010-2016
Figure 8.11 The UK Neuromodulation Devices Market Forecast ($bn), 2016-2021
Figure 8.12 The Italian Neuromodulation Devices Market Forecast ($bn), 2010-2016
Figure 8.13 The Italian Neuromodulation Devices Market Forecast ($bn), 2016-2021
Figure 8.14 The Spanish Neuromodulation Devices Market Forecast ($bn), 2010-2016
Figure 8.15 The Spanish Neuromodulation Devices Market Forecast ($bn), 2016-2021
Figure 8.16 The Chinese Neuromodulation Devices Market Forecast ($bn), 2010-2016
Figure 8.17 The Chinese Neuromodulation Devices Market Forecast ($bn), 2016-2021
Figure 8.18 The Indian Neuromodulation Devices Market Forecast ($bn), 2010-2016
Figure 8.19 The Indian Neuromodulation Devices Market Forecast ($bn), 2016-2021
Figure 8.20 Rest of the World Neuromodulation Devices Market Forecast ($bn), 2010-2016
Figure 8.21 Rest of the World Neuromodulation Devices Market Forecast ($bn), 2016-2021
Companies Listed
Advanced Bionics
Advanced Neuromodulation Systems (ANS)
Aleva Neurotherapeutics
AMS group
Apnex Medical
Atrotech
Australian Therapeutic Goods Administration (TGA)
Autonomic Technologies
Avery Biomedical
Berman Medical
BioControl Medical
Biotronik
Boston Scientific
Cardiac Concepts
Cerbomed
CerebralRx
Cochlear Ltd.
Coridea
CVRx
Cyberonics
DePuy
EBR Systems
ElectroCore
EnteroMedics
Envoy Medical
Eucomed
European Commission (EC)
Food and Drug Administration (FDA)
Functional Neuromodulation
ImThera Medical
Inspire Medical Systems
Intelect Medical
International Neuromodulation Society
IntraPace
Johnson & Johnson (J&J)
Magstim
Med El
Medtronic
MetaCure
MicroTransponder
Nanoretina Inc.
National Epilepsy Foundation
Neurelec
Neurologix
Neuronetics
NeuroPace
Neuros Medical
Neurosigma
Neurotech
Neurowave Medical Technologies
Nevro
Nihon Kohden Corporation
Northstar Neuroscience
Northwestern University
Respicardia
Retina Implant AG
Second Sight Medical Products
Setpoint Medical
Spinal Modulation
SPR Therapeutics
St. Jude Medical
Synapse Biomedical
The International Neuromodulation Society
Transneuronix
Uroplasty
U.S. Centers for Disease Control (CDC)
World Health Organization
To order this report:
Pathology Industry: Neuromodulation Devices: World Market Prospects 2011-2021
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article